ArticleIrish journal of medical science2026
Circulating fibroblast growth factor-21 in coronary artery disease: a systematic review and meta-analysis.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibroblast growth factor-21 (FGF21) is a metabolic regulator involved in glucose and lipid homeostasis and has emerged as a potential biomarker in cardiometabolic diseases. The relationship between circulating FGF21 levels and coronary artery disease (CAD) remains unclear. We performed a systematic review and meta-analysis to clarify this association and assess its clinical relevance.
methodsPubMed, Web of Science, and Scopus were searched for observational studies reporting circulating FGF21 levels in adult CAD patients. Standardized mean differences (SMDs) with 95% confidence intervals were calculated using a random-effects model. Subgroup and meta-regression analyses were conducted to explore heterogeneity.
resultsFourteen studies including 2963 CAD patients were analyzed. Circulating FGF21 levels were significantly higher in CAD patients than in controls (SMD = 0.90; 95% CI: 0.26-1.54; p = 0.0056). In acute CAD, the increase was more pronounced (SMD = 1.70; 95% CI: 0.20-3.21). Elevated FGF21 persisted even when diabetes prevalence was low (SMD = 1.50; 95% CI: 0.15-2.84). Meta-regression identified BMI and HDL as independent contributors to inter-study variability. Sensitivity analyses confirmed robustness, and no strong evidence of publication bias was detected.
conclusionsCirculating FGF21 is elevated in CAD, primarily reflecting metabolic disturbances-particularly adiposity and dyslipidemia-rather than diabetes or CAD itself. Levels tend to be higher during acute events, suggesting that FGF21 may serve as a marker of metabolic stress and lipid abnormalities rather than a direct diagnostic biomarker.
Indexed as
Identifiers
42230515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.